{"entity":{"id":"nct07368998","kind":"trial","name":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer","aka":[],"tldr":"A phase 2 trial of Inavolisib and Fulvestrant in advanced solid tumours, run by Hoffmann-La Roche, now recruiting.","summary":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer is a phase 2 interventional study registered as NCT07368998 by Hoffmann-La Roche, with 80 participants planned, started 2026-02-18 and due to reach its primary completion in 2028-10-31. Interventions recorded: Inavolisib and Fulvestrant.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07368998","url":"https://clinicaltrials.gov/study/NCT07368998"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["inavolisib","fulvestrant"],"companies":["flatiron-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07368998","phase":"2","setting":"A Phase II, Randomized, Open-Label Study Evaluating Two Inavolisib Dose Levels in Combination With Fulvestrant in Participants With PIK3CA-Mutated, HR-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer","sponsor":"Hoffmann-La Roche","enrolled":80,"outcomes":[]},"route":"/trials/nct07368998/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"},{"id":"inavolisib","kind":"drug","name":"Inavolisib","route":"/drugs/inavolisib/"}],"company":[{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/"}]}}